Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS phase 2 study of INCB000928 in fibrodysplasia ossificans progressiva
NL-OMON54122Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing INCB000928 with Placebo (2 arms). Primary endpoint: Total volume of new heterotopic ossification at Week 24. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
zilurgisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON54122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54122.